Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress

ABSTRACT PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2018-03, Vol.119 (3), p.2460-2469
Main Authors: Bahrami, Afsane, Khazaei, Majid, Hasanzadeh, Malihe, ShahidSales, Soodabeh, Joudi Mashhad, Mona, Farazestanian, Marjaneh, Sadeghnia, Hamid Reza, Rezayi, Majid, Maftouh, Mina, Hassanian, Seyed Mahdi, Avan, Amir
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
Activation
AKT protein
Cancer
CELL SURVIVAL
COLORECTAL CANCER
Colorectal carcinoma
Crosstalk
Drug resistance
Inhibitors
MAP kinase
PI3K/AKT/mTOR PATHWAY
Signal transduction
Signaling
Survival
THERAPEUTIC TARGET
TOR protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors in CRC (e.g., BEZ235, NVP‐BEZ235, OSI‐027, everolimus, MK‐2206, KRX‐0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer. J. Cell. Biochem. 119: 2460–2469, 2018. © 2017 Wiley Periodicals, Inc. PI3K/AKT/mTOR signaling pathway is one of the key dysregulated pathways in different tumor types, including colorectal cancer (CRC). Activation of this pathway is shown to be related with cellular transformation, tumor progression, cell survival, and drug resistance. There is growing body of data evaluating the value of PI3K/AKT/mTOR inhibitors (e.g., BEZ235, NVP‐BEZ235, OSI‐027, everolimus, MK‐2206, KRX‐0401, BYL719, and BKM120). This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross talk with ERK/MAPK and mTOR pathways with particular emphasis on the value of targeting this pathway as a potential therapeutic target in treatment of colorectal cancer.
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.25950